Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

Now, new data from the POD1UM-303 study reported at ESMO suggests the company could resurrect the SCAC indication and move Zynyz into the first-line setting to boot. Given in combination with ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – showed that nearly two-thirds (61.6%) of patients with brain metastases ...

Shares of Sutro Biopharma (NASDAQ:STRO) fell by 17% in September after the company's ESMO (European Society for Medical Oncology) update. 3-year performance isn't looking much better at -81% ...

Here you will find news stories and blog posts about the research our scientists have presented at the congress over the years. ESMO Virtual Plenary 2022: Major trial shows targeted drug improves ...